Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Falk Ehmann

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Frontiers in Medicine|May 4, 2026
Horizon scanning at EMA: preparing for the medicines of the futurePatrícia Dias Correia, Valentina Cordo', Oriane Blanquie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2014
Cancer drug development and the evolving regulatory framework for companion diagnostics in the European unionFrancesco Pignatti, Falk Ehmann, Robert Hemmings, et al.
Leukemia & Lymphoma|August 23, 2006
Detection of N-RAS and K-RAS in their active GTP-bound form in acute myeloid leukemia without activating RAS mutationsFalk Ehmann, Stefan Horn, Lizet Garcia-Palma, et al.
European Journal of Public Health|February 14, 2013
Modelling the risk-benefit impact of H1N1 influenza vaccinesLawrence D Phillips, Barbara Fasolo, Nikolaos Zafiropoulous, et al.
Nature Reviews. Drug Discovery|February 2, 2013
Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspectiveMarc Maliepaard, Charity Nofziger, Marisa Papaluca, et al.
Clinical Pharmacology and Therapeutics|February 9, 2022
Biomarker Qualification at the European Medicines Agency: A Review of Biomarker Qualification Procedures From 2008 to 2020Elisabeth Bakker, Natalie M Hendrikse, Falk Ehmann, et al.
Clinical Pharmacology and Therapeutics|October 28, 2025
A Fast Path from Innovation to Safe and Effective MedicinesPeter Arlett, Falk Ehmann, Ralf Herold, et al.
Nanomedicine (London, England)|May 10, 2013
Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicinesFalk Ehmann, Kumiko Sakai-Kato, Ruth Duncan, et al.
Blood|October 25, 2012
Biosimilars: what clinicians should knowMartina Weise, Marie-Christine Bielsky, Karen De Smet, et al.
Nucleic Acid Therapeutics|January 4, 2024
Report of the European Medicines Agency Conference on RNA-Based MedicinesFalk Ehmann, Andreas Kuhn, Anna Maria Gerdina Pasmooij, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Frontiers in Medicine|May 4, 2026
Horizon scanning at EMA: preparing for the medicines of the futurePatrícia Dias Correia, Valentina Cordo', Oriane Blanquie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2014
Cancer drug development and the evolving regulatory framework for companion diagnostics in the European unionFrancesco Pignatti, Falk Ehmann, Robert Hemmings, et al.
Leukemia & Lymphoma|August 23, 2006
Detection of N-RAS and K-RAS in their active GTP-bound form in acute myeloid leukemia without activating RAS mutationsFalk Ehmann, Stefan Horn, Lizet Garcia-Palma, et al.
European Journal of Public Health|February 14, 2013
Modelling the risk-benefit impact of H1N1 influenza vaccinesLawrence D Phillips, Barbara Fasolo, Nikolaos Zafiropoulous, et al.
Nature Reviews. Drug Discovery|February 2, 2013
Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspectiveMarc Maliepaard, Charity Nofziger, Marisa Papaluca, et al.
Clinical Pharmacology and Therapeutics|February 9, 2022
Biomarker Qualification at the European Medicines Agency: A Review of Biomarker Qualification Procedures From 2008 to 2020Elisabeth Bakker, Natalie M Hendrikse, Falk Ehmann, et al.
Clinical Pharmacology and Therapeutics|October 28, 2025
A Fast Path from Innovation to Safe and Effective MedicinesPeter Arlett, Falk Ehmann, Ralf Herold, et al.
Nanomedicine (London, England)|May 10, 2013
Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicinesFalk Ehmann, Kumiko Sakai-Kato, Ruth Duncan, et al.
Blood|October 25, 2012
Biosimilars: what clinicians should knowMartina Weise, Marie-Christine Bielsky, Karen De Smet, et al.
Nucleic Acid Therapeutics|January 4, 2024
Report of the European Medicines Agency Conference on RNA-Based MedicinesFalk Ehmann, Andreas Kuhn, Anna Maria Gerdina Pasmooij, et al.
Pageof 2